Daniel Kraus

Dr. Daniel Kraus


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Judith HaschkaJudith Haschka
Judith Haschka
DKDaniel Kraus
Daniel Kraus
MBMartina Behanova
Martina Behanova
SHStephanie Huber
Stephanie Huber
JBJohann Bartko
Johann Bartko
RKRoland Kocijan
Roland Kocijan
Crohn’s disease (CD) is associated with bone loss and increased fracture risk. TX-Analyzer™ is a new fractal-based technique to evaluate bone microarchitecture based on conventional radiographs. The aim of the present study was to evaluate the TX-Analyzer™ of the thoracic and lumbar spine in CD patients and healthy controls (CO) and to correlate the parameters to standard imaging techniques. 39 CD patients and 39 age- and sex-matched CO were analyzed. Demographic parameters were comparable between CD and CO. Bone structure value (BSV), bone variance value (BVV) and bone entropy value (BEV) were measured at the vertebral bodies of T7 to L4 out of lateral radiographs. Bone mineral density (BMD) and trabecular bone score (TBS) by dual energy X-ray absorptiometry (DXA) were compared to TX parameters. BSV and BVV of the thoracic spine of CD were higher compared to controls, with no difference in BEV. Patients were further divided into subgroups according to the presence of a history of glucocorticoid treatment, disease duration > 15 years and bowel resection. BEV was significantly lower in CD patients with these prevalent risk factors, with no differences in BMD at all sites. Additionally, TBS was reduced in patients with a history of glucocorticoid treatment. Despite a not severely pronounced bone loss in this population, impaired bone quality in CD patients with well-known risk factors for systemic bone loss was assessed by TX-Analyzer™.

5 May 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
Stefan PilzStefan Pilz
Stefan Pilz
Pawel PludowskiPawel Pludowski
Pawel Pludowski
DKDaniel Kraus
Daniel Kraus
LSLisa Schmitt
Lisa Schmitt
URUwe Riedmann
Uwe Riedmann
Background/Objectives: An Endocrine Society Clinical Practice Guideline on vitamin D was published in 2024. Its main objective was the use of vitamin D to lower the risk of disease in individuals without established indications for vitamin D treatment or 25-hydroxavitamin D (25(OH)D) testing. The methodology followed the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) and the Evidence-to-Decision (EtD) framework. Evidence from randomized controlled trials (RCTs) retrieved by a systematic review was prioritized to inform this guideline. It was concluded that vitamin D supplementation reduces rickets and respiratory tract infections in children, mortality in individuals aged 75 years or older, pregnancy complications (outcomes), and progression of prediabetes to diabetes mellitus. Consequently, empiric vitamin D supplementation was recommended for individuals aged 1 to 18 years and ≥75 years, pregnant women, and individuals with prediabetes. Empiric vitamin D supplementation is defined as a vitamin D intake that exceeds the Dietary Reference Intakes (DRIs) and is implemented without 25(OH)D testing. Methods: This article provides a comprehensive guideline summary and critical appraisal based on a narrative review on scientific publications regarding that guideline. Results: Several publications discussed the 2024 Endocrine Society Clinical Practice Guideline on vitamin D. The main criticisms and discussion relate to unclear vitamin D dosages, guideline applicability to certain populations including controversy with previous vitamin D guidelines, and the implications of 25(OH)D testing. Conclusions: The 2024 Endocrine Society Clinical Practice Guideline on vitamin D followed a rigorous methodological approach with high quality standards but it leaves many open questions and uncertainties warranting clarification.

16 June 2023 in Osteologie
Verified
Journal Article
Closed access
DKDaniel Kraus
Daniel Kraus
AMAmadea Medibach
Amadea Medibach
JFJulia Feurstein
Julia Feurstein
MBMartina Behanova
Martina Behanova
JHJudith Haschka
Judith Haschka
RKRoland Kocijan
Roland Kocijan
Introduction Fatigue can be a serious problem among chronically ill patients, but may be overlooked by other more severe disease symptoms. There is not much evidence on fatigue and quality of life (QoL) in patients with rare bone diseases. Thus, the purpose of the study was to assess and compare the prevalence of fatigue and QoL in rare bone disease patients (RARE), patients with osteoporosis (OPO) and healthy controls (CTRL). Methods This monocentric, cross-sectional study was carried out two years in a hospital affiliated with the Vienna Bone and Growth Center (European Reference Network – ERN BOND). The study comprised four types of RARE: Osteogenesis imperfecta, Hypophosphatasia, X-linked Hypophosphatemia and Ehlers Danlos syndrome. Fatigue was assessed by Fatigue Severity Scale (FSS). A higher score indicates more fatigue severity. Health-related quality of life (HRQoL) was assessed by Short-Form Health Survey (SF-36) including physical component (PCS) and mental component summary scores (MCS), which were calculated and normalised to a general population. A higher score indicates better HRQoL. Age-adjusted ANCOVA was used to assess differences in PCS and MCS between groups. Results In total, 54 RARE patients [Mean age (SD) 47.9 (16.0), 75.9% female], 53 OPO patients [66.7 (9.9), 88.7% female] and 52 controls [50.8 (16.3), 73.1% female] were included. The overall Cronbach's α coefficient of the SF-36 was 0.889 and of the FSS 0.922. There were significant differences in fatigue between the 3 groups (p=0.006). Severe fatigue (FSS≥4) was reported by 38.0% of RARE patients, 20.8% OPO patients and by 11.5% controls. Both scores, PCS and MCS were significantly lower in RARE than OPO (p-value 0.002 and 0.007) and CTRLs (p<0.001 for both). Despite higher age in OPO, no significant differences in PCS and MCS were found between OPO and CTLs. Age-adjusted means (95%CI) of PCS and MCS in RARE were 36.1 (32.4-39.7) and 49.6 (46.2-53.1), in OPO 51.5 (46.4-56.6) and 50.2 (45.3-55.0), CTRL 45.2 (42.0-48.5) and 52.8 (49.8-55.9), respectively. FSS score was negatively correlated with physical and mental component in RARE (ρ=-0.45, p=0.002 and ρ=-0.57, p<0.001, respectively) and OPO patients (ρ=-0.32, p=0.03 and ρ=-0.36, p=0.01, respectively). Discussion The QoL in adult patients with rare bone diseases is lower than compared to osteoporotic and control group. Fatigue has significant negative impact on QoL and it is important to address it when meeting with RARE patients in clinical practice. Keywords rare bone disease, health related quality of life, SF-36, FSS, fatigue Korrespondenzadresse Daniel Arian Kraus, Ludwig Boltzmann Institut für Osteologie, Heinrich-Collin-Straße 30, 1140 Wien, Österreich, E-Mail: daniel.arian.kraus@gmail.com Article published online: 16 June 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

16 June 2023 in Osteologie
Verified
Journal Article
Closed access
DKDaniel Kraus
Daniel Kraus
AMAmadea Medibach
Amadea Medibach
MBMartina Behanova
Martina Behanova
AKAnnemarie Kocijan
Annemarie Kocijan
JHJudith Haschka
Judith Haschka
RKRoland Kocijan
Roland Kocijan
Introduction Nutrition plays an important role in patients with bone diseases. Specifically, patients with rare bone diseases (RBD) have decreased mobility thus being of higher risk for obesity and related disorders such as cardiovascular diseases. Currently there is no cure for RBD, therefore lifestyle management and healthy nutrition is of crucial importance. Methods This analysis is part of the ICAM-study, a monocentric, cross-sectional study carried out in a reference hospital affiliated with the Vienna Bone and Growth Center (European Reference Network – ERN BOND). We compared the prevalence of nutritional behavior in patients with RBD (Osteogenesis imperfecta, Hypophosphatasia, X-linked Hypophosphatemia and hypermobile Ehlers Danlos syndrome), osteoporosis (OPO) and healthy controls (CTRL). The nutritional questionnaire consisted of 28 items. BMI was calculated and categorized according to the WHO guidelines. Results The study comprised 54 RBD patients [Mean age (SD) 47.9 (16.0), 75.9% female], 53 OPO patients [Mean age (SD) 66.7 (9.9), 88.7% female] and 52 CTRLs [Mean age (SD) 50.8(16.3), 73.1% female]. Overweight was found in 52% of RBD patients. The prevalence of obesity (BMI ≥ 30) in RBD patients was 24%, in OPO 8.2% and in CTRLs 22.2%. Daily consumption of at least 5 portions of fruits and/or vegetables was observed in 10% of RBD, 17.3% of OPO and 9.6% of CTRLs (p=0.407). At least 3 dairy products daily as complied with Austrian recommendations was reported by 16% of RBD, 17% of OPO and 11.5% of CTRLs (p=0.707). A vegetarian lifestyle was stated in 8% of RBD, 9% of OPO and 14% of CTRLs. The meat intake was generally in the recommended range. Recommended fish intake was only fulfilled by 2% of RBD, 4% of OPO and 14% of CTRLs. Discussion A significant proportion of RBD patients do not follow healthy lifestyle recommendations for general population. Specific nutrition recommendations for RBD patients considering body weight and BMI control are of crucial importance. Considering physical limitations related to the severity of disease, RBD patients should be advised to watch their daily nutritional intake. Keywords rare bone disease, hypophosphatasia, osteogenesis imperfecta, x-linked hypophosphatemia, obesity, osteoporosis, nutrition, healthy lifestyle Korrespondenzadresse Daniel Arian Kraus, Ludwig Boltzmann Institut für Osteologie, Heinrich-Collin-Straße 30, 1140 Wien, Österreich, E-Mail: daniel.arian.kraus@gmail.com Article published online: 16 June 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

1 August 2022 in Osteologie
Verified
Journal Article
Closed access
DKDaniel Kraus
Daniel Kraus
JHJudith Haschka
Judith Haschka
SHStephanie Huber
Stephanie Huber
ESE Jakob Schanda
E Jakob Schanda
MBMartina Behanova
Martina Behanova
RKRoland Kocijan
Roland Kocijan
Introduction Osteogenesis imperfecta is a rare genetic disorder characterized by impaired bone quality and quantity. TX-Analyzer is a new fractal-based technique assessing bone microstructure based on conventional radiographs. We explored whether TX-Analyzer can discriminate osteogenesis imperfecta patients from controls and investigated the correlation between TX-Analyzer and crucial imaging techniques. Methods 29 osteogenesis imperfecta patients and 58 age- and gender-matched controls were analyzed. The parameters bone structure value, bone variance value and bone entropy value were measured at the vertebral bodies of T7 to L4. Furthermore, bone mineral density by dual energy x-ray absorptiometry, trabecular bone score and trabecular bone microstructure by high-resolution peripheral quantitative computed tomography were correlated to them. The accuracy of TX-Analyzer in detecting osteogenesis imperfecta was assessed with area under curve analysis of receiver operating characteristic. Results Bone entropy value of thoracic and lumbar spine were significantly lower in osteogenesis imperfecta patients compared to controls (both p<0.001). Bone entropy value of the thoracic spine correlated significantly to trabecular bone score (ρ=0.427, p=0.042) as well as trabecular number (ρ=0.603, p=0.029) and inhomogeneity of the trabecular network (ρ=−0.610, p=0.027) at the radius. No correlations were found between bone entropy value and bone mineral density. Bone entropy value of thoracic and lumbar spine had an area under the curve of 0.81 (p<60;0.001) and 0.73 (p=0.008), respectively. Discussion The TX-Analyzer can discriminate patients with osteogenesis imperfecta from controls. Low to no correlations with conventional methods suggest,that the TX-Analyzer may indicate a new and independent examination tool in osteogenesis imperfecta. Keywords Osteogenesis imperfecta, TX-Analyzer, fractal-based analysis, bone microstructure, conventional radiography Korrespondenzadresse Daniel Arian Kraus, Ludwig Boltzmann Institut für Osteologie, Heinrich-Collin-Straße 30, 1140 Wien, Österreich, E-Mail: daniel.arian.kraus@gmail.com Article published online: 08 September 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

1 August 2022 in Osteologie
Verified
Journal Article
Closed access
DKDaniel Kraus
Daniel Kraus
Introduction Male idiopathic osteoporosis (MIO) is a chronic condition leading to low-traumatic fractures and requires transiliac bone biopsy for further clarification. In the present study we evaluated transiliac bone biopsy specimens retrospectively to identify the most common reasons for MIO. Methods Bone biopsy specimens of 30 male adults aged 44.6±13 (mean±SD) were analyzed histomorphometrically by microscopy and quantitative backscattered electron imaging and were compared to a reference database. Furthermore, demographic data, laboratory results including bone turnover markers, bone mineral density (BMD) and trabecular bone score by DXA were assessed. Results BMD measurements at lumbar spine and total hip revealed osteoporotic (46.4%;44.4%), osteopenic (39.3%;40.7%) and normal (14.3%;14.8) values (mean -2.3±1.8;-2.0±1.4), respectively. TBS was 1.3±0.1. Laboratory results including bone turnover markers and testosterone were generally in normal range. The static histomorphometry parameters were decreased in MIO patients: bone volume (46.6%), trabecular number (23.3%) and trabecular thickness (46.7%) compared to reference values (Z-score<-1SD). Dynamic histomorphometry parameters were available in 8 subjects. An increase in osteoid volume and mineralizing surface was found in 28.6% of patients (Z-score>1SD). Mineralizing surface was decreased in 42.9% (Z-score<-2SD). Bone formation rate was elevated (28.6%, Z-score>1SD), decreased (28.6%, Z-score<-1SD) or normal (42.9%, Z-score 0±1SD). An increase in osteoid surface (Z-score>2SD) or decrease (Z-score<-2SD) in osteoblast surface was found in 50% of subjects. Discussion MIO is a heterogenous group of bone diseases. The most common biopsy findings were low-turnover osteoporosis/osteopenia (40%), defects in bone microstructure (37%) and defects in mineralization/osteomalacia (40%). Bone biopsies are mandatory to differ the various causes of MIO and to initiate specific treatment. Keywords Male Idiopathic Osteoporosis, Bone Biopsy, Histomorphometry, Osteomalacia, fragility Fracture Korrespondenzadresse Daniel Arian Kraus, Ludwig Boltzmann Institut für Osteologie, Heinrich-Collin-Straße 30, 1140 Wien, Österreich, E-Mail: daniel.arian.kraus@gmail.com Article published online: 08 September 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany